Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Vaccines01:30

Cancer Vaccines

932
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
932
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer02:18

Cancer

53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same author

Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials.

JCO oncology practice·2026
Same author

Pancreatic Cancer: Translating Tumor Biology into Actionability.

Cancer discovery·2026
Same author

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Radiogenomics and the DNA damage response: opportunities for biomarker-guided radiosensitization in pancreatic cancer.

Frontiers in oncology·2026
Same author

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Nature communications·2026

相关实验视频

Updated: Jan 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

瘤基因突变:共享的抗原疫苗有效吗?

Rodrigo Paredes1,2, S Daniel Haldar3, Shubham Pant3

  • 11Icahn School of Medicine, Mount Sinai Morningside-West, New York, NY, USA.

Annual review of medicine
|December 5, 2025
PubMed
概括

针对共享突变的瘤基因导向癌症疫苗为新抗原疫苗提供了一个可扩展的替代方案. 这些疫苗在针对各种癌症的临床试验中显示出前景,特别是在最小残留疾病环境中.

更多相关视频

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K

相关实验视频

Last Updated: Jan 9, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 疫苗学 疫苗学 疫苗学

背景情况:

  • 癌症免疫疗法通过免疫检查点抑制剂和T细胞疗法取得了进展.
  • 在克服瘤免疫逃避方面仍然存在挑战.
  • 新抗原疫苗看起来很有前途,但由于瘤异质性而面临可扩展性问题.

研究的目的:

  • 审查瘤基因导向癌症疫苗的演变.
  • 讨论它们的临床影响和潜力.
  • 探索未来优化疫苗疗效的战略.

主要方法:

  • 对基因定向疫苗的临床试验数据的审查.
  • 分析共享的致癌驱动突变 (例如,KRAS,EGFR,IDH) 作为疫苗点.
  • 探索疫苗,辅助剂和免疫调节方面的进展.

主要成果:

  • 共享的致癌驱动突变提供了一个稳定且广泛适用的疫苗策略.
  • 临床试验证明了这些疫苗的免疫性.
  • 在最小残留疾病环境中显示出潜力.

结论:

  • 针对癌基因的疫苗代表了癌症免疫治疗的有希望的,可扩展的方法.
  • 预计在分娩和免疫调节方面的进一步进展将提高疗效.
  • 这些疫苗具有治疗各种癌症的巨大潜力,特别是在克服免疫逃避方面.